18 September 2018
Visiongain has launched a new pharma report Cell-Based Assays World Industry and Market 2018-2028: Drug Discovery, Basic Research, Predictive Technology, Instrument, Consumables, Software, Services, Reagents, Assay Kits, Microplates, Cell Lines, Probes & Labels, Pharma & Biotech Companies, Academic Institutes, CROs.
Cell-based assays hold a number of advantages over traditional biochemical assays and animal models, and these advantages have driven the increased demand for these assays in recent years. There has been an increased usage of cell-based assays as the preferred tool for screening potential drug compounds and toxicity screening, thus growing demand by drug development companies. The demand for cell-based assays will expand further due to increased allocation of resources towards drug discovery by companies, the presence of a large number of proteins which still have unknown functions, and the rising demand for biological drugs.
The lead analyst of the report commented "Whilst there are many factors driving growth in the cell-based assays market, market challenges still exist. Even though the cost of cell-based assays is gradually declining as the technology advances, the overall cost of cell-based assays and the equipment required to run them and analyse the data, is still high.
Another restraint is the complexity of cell-based assays, and the need for skilled individuals to run them and to analyse the data from them. The complexities of these assays also mean that the development of innovative new assays and products by cell-based assay companies is costly and can take a long time."
Leading companies featured in the report include BD (Becton, Dickinson and Company), BioAgilytix Labs, BioVision, Cell Assay Innovations, Inc., Charles River Laboratories International, CYTOO SA, DiscoverX, GE Healthcare, InSphero,Marin Biological Laboratories, Molecular Devices, Perkin Elmer, Pharmaceutical Product Development, Porsolt, Promega, ProQinase GmbH, QGel, SGS Group, Inc., Thermo Fisher Scientific (and Affymetrix acquisition)
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The global vaccines market is one that is driven by innovation. This is vital for maintaining the rich pipeline of vaccines seen in the human vaccines market.
05 July 2019
Opportunities in the market stem from the increasing use of specialist and generic drugs, which have higher profit margins; global expansion into the emerging markets; vertical integration of wholesalers; and the increasing use of pharmaceuticals.
28 June 2019
Progress in R&D in the therapeutic vaccine field will yield revolutionary results and answer unmet medical needs. This will also lead to more innovative approaches to vaccine development.
25 June 2019
Revenue growth will be driven by rising incidence and prevalence owing to modern lifestyles and improved awareness and diagnosis.